TABLE 1.
List of the current active clinical trials targeting EGF and TGF-β signaling pathways in combination with chemotherapeutics.
| Target class | Functional class | Drug name | chemotherapeutics combination | Cancer type | Clinical status (first posted, recruitment status) | Intervention/treatment |
| TGF-β/TGF-β Receptor inhibitors | Tyrosine kinase inhibitor | LY-2152799 (Galunisertib) | Fluorouracil/Capecitabine + Tumor specific mesorectal excision | Locally Advanced Rectal Adenocarcinoma | NCT02688712 (2016, Recruiting) | Drug: LY2157299Drug: Capecitabine Drug: Fluorouracil Procedure: Tumor specific mesorectal excision |
| Paclitaxel/Carboplatin | Carcinosarcoma of the Uterus or Ovary | NCT03206177 (2017, Recruiting) | Drug: Galunisertib Drug: Paclitaxel Drug: Carboplatin | |||
| Sorafenib | Advanced Hepatocellular Carcinoma | NCT02178358 (2014, Active, not recruiting) | Drug: LY2157299 Drug: Sorafenib Drug: Placebo | |||
| TGF-β receptor inhibitor | TEW-7197 | Pomalidomide | Relapsed or Relapsed and Refractory Multiple Myeloma | NCT03143985 (2017, Recruiting) | Drug: TEW-7197 Drug: Pomalidomide | |
| EGF/EGFR inhibitors | EGFR tyrosine kinase inhibitor | Gefitinib | Pemetrexed | Advanced Non-Small Cell Lung Cancer | NCT01982955 (2013, Active, not recruiting) | Drug: Tepotinib Drug: Gefitinib Drug: Pemetrexed Drug: Cisplatin Drug: Carboplatin |
| Icotinib | Pemetrexed, Carboplatin | III B/IV Non-Small Cell Lung Cancer | NCT03151161 (2017, Not yet recruiting) | Drug: Icotinib, Pemetrexed, Carboplatin Drug: Icotinib | ||
| Cisplatin or Carboplatin | metastatic non-squamous non-small cell lung cancer who did not progress after pemetrexed combined with platinum chemotherapy | NCT03992885 (2019, Recruiting) | Drug: Icotinib Drug: Cisplatin Drug: Carboplatin | |||
| Apatinib | Pemetrexed, Gemcitabine, Docetaxel | NSCLC Patients Without T790M Mutation | NCT03758677 (2018, Not yet recruiting) | Drug: Apatinib Drug: Chemotherapy with platinum-based double drugs (Pemetrexed, Gemcitabine, Docetaxel) | ||
| Pemetrexed Plus Carboplatin | Advanced Non-small Cell Lung Cancer | NCT03164694 (2018, Recruiting) | Drug: Apatinib + Pemetrexed + Carboplatin Drug: Pemetrexed + Carboplatin | |||
| Osimertinib | Cisplatin or Carboplatin | Metastatic EGFR Mutant Lung Cancers | NCT03567642 (2018, Recruiting) | Drug: Osimertinib Drug: Platinum Drug: Etoposide | ||
| Platinum-based Doublet-Chemotherapy | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT02151981 (2018, Active, not recruiting) | Drug: Chemotherapy Drug: Cross-over to Osimertinib | |||
| Pemetrexed + Cisplatin or Pemetrexed + Carboplatin | Locally Advanced Non-Small Cell Lung Cancer | NCT04035486 (2019, Recruiting) | Drug: Osimertinib Drug: Osimertinib + Pemetrexed + Cisplatin Drug: Osimertinib + Pemetrexed + Carboplatin | |||
| Monoclonal antibody | Panitumumab | Carboplatin and Paclitaxel | Invasive Triple Negative Breast Cancer | NCT02876107 (2016, recruiting) | Drug: Carboplatin Other: Laboratory Biomarker Analysis Drug: Paclitaxel Biological: Panitumumab | |
| HLX07 | Gemcitabine + Cisplatin/Paclitaxel + Carboplatin/mFOLFOX6 | Advanced Solid Tumors | NCT03577704 (2018, Recruiting) | Drug: HLX07 + Gemcitabine + Cisplatin Drug: HLX07 + Paclitaxel + Carboplatin Drug: HLX07 + mFOLFOX6 |